Clinical Trials · NCT06370728
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 30
- Start date
- May 2024
- Locations
- 1 site, United States
- Primary endpoint
- Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC [0-∞]) of Orforglipron